SpyGlass Pharma (SGP) Corporate presentation summary

Value proposition and market opportunity

• Focus on long-acting, sustained drug delivery for chronic eye conditions, targeting open angle glaucoma (OAG) and ocular hypertension (OHT).

• Lead product, BIM-IOL System, addresses a $13 billion U.S. market and is designed for use by all cataract surgeons.

• Platform aims to deliver multiple drugs for both short- and long-term eye conditions.

• Strong intellectual property with patents expiring between 2039 and 2043, and global coverage.

• $251 million in cash and equivalents as of March 31, 2026.

Clinical need and patient journey

• Over 80 million people globally are affected by OAG.

• Non-adherence to daily eye drops is common, leading to disease progression and vision loss.

• BIM-IOL System integrates drug delivery with cataract surgery, aiming to eliminate the need for daily drops.

• Intended for all cataract surgeons, not just those performing MIGS.

Product and clinical development

• BIM-IOL System combines bimatoprost, cataract surgery, and IOL technology for a streamlined intervention.

• Phase 3 pivotal trials are underway, with identical design across two studies, each enrolling ~400 patients.

• FIH trial showed 95% of patients off topical therapy and 37% mean IOP reduction at 36 months.

• Phase 1/2 trial at 78 mcg dose showed 98% off topical therapy and 34% mean IOP reduction at 12 months.

• Safety profile comparable to routine cataract surgery, with no serious ocular adverse events.